[{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ginkgo Bioworks \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Ginkgo Bioworks \/ Moderna"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Recombinant AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0.12,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bioworks \/ Biogen"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"SaponiQx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Saponin-based Adjuvanted Vaccine","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Microba Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Microbiome Based Product","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Cronos Group","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"CBR","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Synlogic","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SYNB2081","moa":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Circularis Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Circular RNA-based Therapeutic","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Esperovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Circular RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Prokarium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Prokarium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ginkgo Bioworks","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"StrideBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Modulus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"}]

Find Clinical Drug Pipeline Developments & Deals by Ginkgo Bioworks

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The partnership aims to enhance the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity, leveraging Ginkgo's synthetic biology platform for new methods.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 10, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Discovery

                          Sponsor : Novo Nordisk

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the acquisition, Ginkgo will get access to the Modulus cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries for solid tumors, autoimmune, etc.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 02, 2024

                          Lead Product(s) : CAR-T Cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Modulus Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 27, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Pfizer Inc

                          Deal Size : $331.0 million

                          Deal Type : Collaboration

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 08, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $406.0 million

                          Deal Type : Partnership

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 05, 2023

                          Lead Product(s) : AAV-based Gene Therapy

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery

                          Recipient : StrideBio

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Proceeds will support clinical development of the Company’s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 09, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Prokarium

                          Deal Size : $30.0 million

                          Deal Type : Financing

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Bactofection, the process of transferring genetic material into a mammalian cell via a bacterium, is an alternative gene delivery system that could deliver therapeutic agents to a patient in RNA-based therapy.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 09, 2023

                          Lead Product(s) : RNA-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Prokarium

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CircRNAs (circular RNA based therapy) represent an emerging, powerful mechanism for delivering therapeutics and vaccines due to their protein-coding potential and improved stability in comparison to their linear mRNA counterparts.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 05, 2023

                          Lead Product(s) : Circular RNA-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Esperovax

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Circularis platform will give Ginkgo the ability to rapidly identify context-specific promoters for cell therapy and circular RNA-based therapeutic applications, such as those that modulate gene expression in the tumor microenvironment.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 04, 2022

                          Lead Product(s) : Circular RNA-based Therapeutic

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Recipient : Circularis Biotechnologies

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank